438220-19-0

Usage

Uses

Used in Pharmaceutical Research:
4-(2,5-DIMETHYL-PHENYL)-5-METHYL-THIAZOL-2-YLAMINE is used as a building block for the synthesis of biologically active molecules, contributing to the development of novel pharmaceutical agents. Its unique structure allows for the creation of diverse compounds with potential therapeutic effects.
Used in Drug Development:
In the pharmaceutical industry, 4-(2,5-DIMETHYL-PHENYL)-5-METHYL-THIAZOL-2-YLAMINE is utilized in the development of new drugs, leveraging its chemical properties to enhance the efficacy and selectivity of medicinal compounds.
Used as a Reagent in Organic Chemical Reactions:
4-(2,5-DIMETHYL-PHENYL)-5-METHYL-THIAZOL-2-YLAMINE also serves as a reagent in organic chemical reactions, facilitating the synthesis of complex organic molecules and aiding in the advancement of chemical research and innovation.

InChI:InChI=1/C12H14N2S/c1-7-4-5-8(2)10(6-7)11-9(3)15-12(13)14-11/h4-6H,1-3H3,(H2,13,14)

Upstream product

• 35031-52-8 1-(2,5-dimethylphenyl)propan-1-one 

Relevant academic research and scientific papers

Structure-activity relationship studies in substituted sulfamoyl benzamidothiazoles that prolong NF-κB activation

In the face of emerging infectious diseases, there remains an unmet need for vaccine development where adjuvants that enhance immune responses to pathogenic antigens are highly desired. Using high-throughput screens with a cell-based nuclear factor κB (NF-κB) reporter assay, we identified a sulfamoyl benzamidothiazole bearing compound 1 that demonstrated a sustained activation of NF-κB after a primary stimulus with a Toll-like receptor (TLR)-4 agonist, lipopolysaccharide (LPS). Here, we explore systematic structure–activity relationship (SAR) studies on compound 1 that indicated the sites on the scaffold that tolerated modification and yielded more potent compounds compared to 1. The selected analogs enhanced release of immunostimulatory cytokines in the human monocytic cell line THP-1 cells and murine primary dendritic cells. In murine vaccination studies, select compounds were used as co-adjuvants in combination with the Food and Drug Administration approved TLR-4 agonistic adjuvant, monophosphoryl lipid A (MPLA) that showed significant enhancement in antigen-specific antibody titers compared to MPLA alone. Additionally, our SAR studies led to identification of a photoaffinity probe which will aid the target identification and mechanism of action studies in the future.